Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 50 years, inclusive.~* Acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms, and with signs referable to the symptoms; in the absence of a fever or active infection.~* Diagnosis of a relapsing form of multiple sclerosis before randomization as determined by Poser or McDonald Criteria.~* Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.~* Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction.~* New objective clinical finding other than a sensory exacerbation, or bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis.~* Subjects may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids should discontinue immunomodulatory treatment.~* Understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care.~Exclusion Criteria:~* Any patients treated with systemic corticosteroid use within one month of the index episode at screening.~* Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, IVIg) or plasmapheresis.~* Any patient who is pregnant or breastfeeding.~* Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).~* Peripheral or cranial neuropathy as sole problem of acute episode.~* History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy.~* Primary Progressive Multiple Sclerosis (PPMS).~* Previous participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- megadose oral methylprednisolone (Type: EXPERIMENTAL): 1400 mg qd/5 days
- IV methylprednisolone (Type: EXPERIMENTAL): 1000 mg/qd/5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).